Remepy secures $36m funding for hybrid drug pipeline expansion
Remepy secured $36 million in Series A funding, led by OG Venture Partners and M Ventures, bringing total capital to $62 million. The funds will support the global Phase III clinical trial for its lead product, Hybridopa, targeting Parkinson’s disease, commencing in Q4 2026. Remepy develops hybrid drugs combining prescription medicines with AI-driven therapeutic applications. This financing aids pipeline expansion and strategic partnerships, including a recent collaboration with Merck KGaA.
A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.